Compare Mesoblast Limited (MESO) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Newegg Commerce Inc — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Newegg Commerce Inc trades at $11.58 (market cap $243.30M). The key difference: Mesoblast Limited is far larger — about 7.2× Newegg Commerce Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Newegg Commerce Inc for 14 Days on average.
| MESO | NEGG | |
|---|---|---|
Market Cap | $1.75B | $243.30M |
Volume | 239,027 | 41,252 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $92.74 |
52-Week Low | $13.19 | $11.49 |
Typical Hold Time | 15 Days | 14 Days |
Enterprise Value | $1.83B | $213.53M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Newegg Commerce (NEGG) trades at $11.58, down 3.58% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $1.4B and net income turning positive in 2026 forecasts. Recent partnerships with Western Digital and Hewlett Packard Enterprise highlight strategic positioning in AI and IT infrastructure markets. However, negative operating cash flow and insider selling activity present near-term concerns.
The stock faces mixed signals with strong analyst buy ratings (100% consensus) but a $7.75 price target below current levels. Improving profitability trends and strategic partnerships provide upside potential, while cash flow challenges and competitive pressures remain key risks. The current valuation at 0.18 P/S appears attractive if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
